Sientra (SIEN) Upgraded by Stifel Nicolaus to “Buy”

Sientra (NASDAQ:SIEN) was upgraded by investment analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage presently has a $14.00 price target on the medical instruments supplier’s stock. Stifel Nicolaus’ price target points to a potential upside of 20.07% from the company’s previous close.

SIEN has been the topic of a number of other research reports. BidaskClub upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Friday, December 15th. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Canaccord Genuity restated a “buy” rating and set a $19.00 price target on shares of Sientra in a research note on Friday, January 5th. Finally, ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $15.00.

Sientra (NASDAQ:SIEN) traded up $1.33 during mid-day trading on Friday, reaching $11.66. The company’s stock had a trading volume of 961,848 shares, compared to its average volume of 158,579. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.92 and a current ratio of 2.87. Sientra has a twelve month low of $7.20 and a twelve month high of $16.68. The stock has a market capitalization of $200.42, a price-to-earnings ratio of -4.09 and a beta of -1.47.

Sientra (NASDAQ:SIEN) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.06). Sientra had a negative return on equity of 68.82% and a negative net margin of 169.77%. The business had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $10.54 million. During the same quarter in the previous year, the business earned ($0.55) EPS. The business’s revenue for the quarter was up 50.8% on a year-over-year basis. equities research analysts forecast that Sientra will post -3.23 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new position in shares of Sientra during the second quarter valued at $101,000. Nationwide Fund Advisors increased its stake in shares of Sientra by 260.4% during the second quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 7,921 shares during the period. New York State Common Retirement Fund purchased a new position in shares of Sientra during the second quarter valued at $148,000. Rhumbline Advisers purchased a new position in shares of Sientra during the second quarter valued at $158,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Sientra by 23.4% during the second quarter. Dimensional Fund Advisors LP now owns 18,660 shares of the medical instruments supplier’s stock valued at $181,000 after buying an additional 3,534 shares during the period. Hedge funds and other institutional investors own 76.59% of the company’s stock.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/20/sientra-sien-upgraded-by-stifel-nicolaus-to-buy.html.

About Sientra

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply